



22th December 2009

**Company Announcements Office
Australian Securities Exchange**

Nanosonics Company Update

International site testing validates micro-biocidal efficacy of Trophon® EPR

Nanosonics has recently undertaken further micro-biocidal testing of the Trophon EPR. The most recent site testing has been conducted in Israel by an internationally recognised clinical microbiologist from a leading hospital and included “simulated use testing” on ultrasound probes contaminated with high levels of a range of microorganisms and fungi. The results obtained confirmed the in-field clinical data, provided as a response to the FDA enquiries, showed no growth of any organisms after multiple tests of single cycles in the Trophon EPR.

This validation was further reinforced by independent clinical testing in two major clinical sites in Sydney in November. These results continue to confirm the efficacy of the Trophon EPR.

All sites also acknowledge the ease of use of the Trophon EPR in clinical practice and the significant improvements in workflow.

Warm welcome for Nanosonics at world’s largest medical trade fair

Nanosonics received an overwhelming reception at Germany’s Medica 2009 last month. Medica is the world’s largest medical trade fair and registered almost 138,000 trade visitors from over 100 countries.

The tradeshow also presented a perfect opportunity for the Company to meet with its existing distribution partners, who reiterated their enthusiasm to initiate product roll-out of the Trophon EPR in their respective countries. Potential distributors were also identified in new regions such as Japan, Brazil, India, Mexico and Romania.

Nanosonics is also pleased to report that the Trophon EPR product demonstration video was the most downloaded of all interactive media. This recognition emphasises the innovative nature and relevance of the Trophon EPR globally.

If you would like to view the Trophon EPR video, please contact us at info@nanosonics.com.au

**David Radford
Chief Executive Officer**

For more information please contact David Radford, CEO, or Chris Grundy, CFO and Company Secretary, on (+61) 02 8063 1600.

**About Nanosonics**

Nanosonics Limited is developing a portfolio of decontamination products designed to reduce the spread of infection. The Company owns intellectual property relating to a unique disinfection and sterilisation technology which can be suited to a variety of markets.

Initial market applications are designed for the reprocessing of reusable medical instruments. The Company's first product is designed to disinfect Ultrasound Transducers. In parallel with the commercialisation of this product, Nanosonics is also developing other medical applications and exploring opportunities for its proprietary technology in other industries.

For more information about Nanosonics please visit www.nanosonics.com